The standard that COMPare is aiming to achieve, as far as I understand it, is the following:
1. Outcomes that will be measured for clinical trials need to be registered and public ahead of the trial (this is already achieved with recent regulation, as mentioned in the article)
2. If planned outcomes change, the change needs to be reported and explained, with new outcomes being again clearly stated.
I really struggle to see how enforcing this will prevent productive research. This is basic scientific hygiene, not fantasy. No one is arguing that studies shouldn't be adjusted, just that the adjustments should be clearly stated.
Completely changing the goals of a study after failing on your initial goals, and then claiming success without mentioning any of the failures along the way is poor science, because you're masking a lot of potentially significant findings along the way that others can benefit from as well.
Not to mention that these standards have been agreed to by all the largest journals decades ago, with big PR claims of how this is needed etc., yet are never followed in practice. The responses of some journals (NEJM, JAMA that I recall) have been shameful, and contradictory to standards they claim to follow.